Despite 'game-changing' new RSV shots, uptake lagged among infants, adults: Experts

Despite this RSV season having a "game-changing" new set of vaccinations and immunizations, doctors say uptake has lagged among adults and children.

For years, respiratory syncytial virus (RSV) has been the most common reason infants are hospitalized in the U.S. and has hospitalized thousands of elderly people every year.

After decades of trying to develop a vaccine, they became available ahead of this season for the first time for adults aged 60 and older and for pregnant people between 32 weeks' and 36 weeks' gestation.

Additionally, for the first time ever, an injectable monoclonal antibody shot to protect babies aged 8 months and younger and certain high-risk children under 24 months also hit the market.

However, the experience of doctors getting their patients immunized has been varied across the country. Supply chain issues hampered efforts and some parents have been reluctant to vaccinate their children, health care experts told ABC News.